(7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯 | 127199-45-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯
• 中文别名: (S)-7-叔丁氧基羰基氨基-5-氮杂螺[2.4]庚烷；(7S)-5-氮杂螺(2.4)庚烷-7-基氨基甲酸叔丁酯；N-(7S)-5-氮杂螺[2.4]庚烷-7-基-氨基甲酸叔丁酯
• 英文名称: tert-butyl (S)-(5-azaspiro[2.4]heptan-7-yl)carbamate
• 英文别名: (7S)-tert-butoxycarbonylamino-5-azaspiro[2.4]heptane；(S)-tert-Butyl 5-azaspiro[2.4]heptan-7-ylcarbamate；tert-butyl N-[(7S)-5-azaspiro[2.4]heptan-7-yl]carbamate
• CAS: 127199-45-5
• 化学式: C₁₁H₂₀N₂O₂
• 分子量: 212.292
• InChiKey: CGEBPOMWRHSMLI-MRVPVSSYSA-N

物化性质

• 沸点：
  329.0±31.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2942000000
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (S)-7-tert-Butoxycarbonylamino-5-azaspiro[2.4]heptane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (S)-7-tert-Butoxycarbonylamino-5-azaspiro[2.4]heptane
CAS number: 127199-45-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H20N2O2
Molecular weight: 212.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

(7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯是一种有用的研究化学品。

应用

(7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯是有机合成中间体和医药中间体，广泛应用于实验室研发过程和化工医药的合成中。

反应信息

• 作为反应物：
  描述：

  (7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯 在 盐酸 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 5.25h， 生成 西他沙星
  参考文献：
  名称：

  （氟环丙基）喹诺酮类。2.手性7-（7-氨基-5-氮杂螺[2.4]庚-5-基）-1-（2-氟环丙基）喹诺酮类抗菌剂的合成及立体化学构效关系。

  摘要：

  合成一系列新颖的手性7-（7-氨基-5-氮杂螺[2.4]庚-4-基）-8-氯-1-（2-氟代环丙基）-喹诺酮，作为对1的研究项目的延续-（2-氟环丙基）-喹诺酮类化合物，通过考虑分子的立体化学和物理化学性质而确定。通过X射线晶体学分析确定1-（顺-2-氟环丙基）部分和7-（7-氨基-5-氮杂-[2.4]庚-5-基）部分的绝对构型。立体化学结构-活性关系研究表明，1-[（（1R，2S）-2-氟环丙基]和7-[（7S）-氨基-5-azaspiro [2.4]庚-5-基]衍生物对革兰-阳性和革兰氏阴性菌比其他立体异构体和7-[（（7S）-7-氨基-5-氮杂螺[2.4]-庚-5-基] -8-氯-1-[（1R，2S）-2 -氟环丙基]喹诺酮（33）是所有立体异构体中最有效的。

  DOI：

  10.1021/jm00046a019
• 作为产物：
  描述：

  1-乙酰基环丙烷羧酸乙酯 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 5%-palladium/activated carbon 、 ammonium acetate 、 溴 、 ammonium formate 、 sodium cyanoborohydride 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 36.0h， 生成 (7S)-5-氮杂螺[2.4]庚烷-7-基氨基甲酸叔丁酯
  参考文献：
  名称：

  西他沙星五元环侧链中间体的制备方法

  摘要：

  本发明涉及一种西他沙星五元环侧链中间体的制备方法，包括以下步骤：原料1的酮羰基在醋酸铵或氯化铵存在下与氰基硼氢化钠或三醋酸硼氢化钠反应，所得产物的酰胺羰基用四氢铝锂还原，还原产物的游离氨基在碱的存在下与二碳酸二叔丁酯反应，所得产物的苯乙基在钯‑碳的存在下用甲酸或甲酸盐还原脱除，即得所述西他沙星侧链中间体(产物5)。该方法反应条件温和，对设备要求低，制备过程安全，立体选择性好，原料试剂廉价易得，制备成本低。

  公开号：

  CN105330590B

文献信息

• [EN] PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS<br/>[FR] PYRAZOLO[1,5-A]PYRIMIDINES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2011163518A1

  公开（公告）日：2011-12-29

  The invention provides compounds of Formula I or Formula II: (I), (II) or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

  本发明提供了公式I或公式II的化合物：(I)、(II)或其药用可接受的盐或酯，如本文所述。这些化合物及其组合物可用于治疗副粘病毒感染。这些化合物、组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
• [EN] PYRAZOLOTRIAZINES<br/>[FR] PYRAZOLOTRIAZINES
  申请人：BAYER AG

  公开号：WO2021116178A1

  公开（公告）日：2021-06-17

  The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

  本发明提供了具有通用公式（I）的化合物，其中X，R1，R2和R3如本文所述和定义，制备所述化合物的方法，用于制备所述化合物的有用中间化合物，包含所述化合物的药物组合物和组合，以及使用所述化合物用于制造用于治疗和/或预防疾病的药物组合物，特别是作为单一剂或与其他活性成分结合使用的过度增殖障碍，如癌症疾病。
• Processes for preparation of bicyclic compounds and intermediates therefor
  申请人：——

  公开号：US20040019223A1

  公开（公告）日：2004-01-29

  A process for preparing intermediate compound (VII), compound (VIII) and compound (XIV) which will be raw materials for the synthesis of a synthetic antibactrial compound, via compound (I) or compound (X) and then, compound (II), the compounds each being shown below; and novel compounds useful for the preparation. 1

  一种制备中间化合物（VII）、化合物（VIII）和化合物（XIV）的方法，这些化合物将作为合成抗菌化合物的原料，通过化合物（I）或化合物（X）以及化合物（II），每种化合物如下所示；以及用于制备的新化合物。
• Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors
  作者：Jianping Hu、Chang-Qing Tian、Mohammadali Soleimani Damaneh、Yanlian Li、Danyan Cao、Kaikai Lv、Ting Yu、Tao Meng、Danqi Chen、Xin Wang、Lin Chen、Jian Li、Shan-Shan Song、Xia-Juan Huan、Lihuai Qin、Jingkang Shen、Ying-Qing Wang、Ze-Hong Miao、Bing Xiong

  DOI：10.1021/acs.jmedchem.9b01094

  日期：2019.9.26

  target. Therefore, identifying novel inhibitors with distinct properties could enrich their use in anticancer treatment. Guided by the cocrystal structure of hit compound 4 harboring a five-membered-ring linker motif, we quickly identified lead compound 7, which exhibited good antitumor effects in an MM.1S xenograft model by oral administration. Encouraged by its high potency and interesting scaffold,

  BRD4最近已成为有前途的药物靶标。因此，鉴定具有独特性质的新型抑制剂可以丰富其在抗癌治疗中的应用。在具有五元环连接基序的命中化合物4的共晶体结构的指导下，我们快速鉴定了先导化合物7，该化合物在口服MM.1S异种移植模型中显示出良好的抗肿瘤作用。受其高效能和有趣的支架的鼓舞，我们进行了进一步的前导优化，以生成具有（1,2,4-triazol-5-yl）-3,4-的新型有效的bromodomain和末端外（BET）抑制剂系列。二氢喹喔啉-2（1 H）-一个结构。其中，化合物19被发现具有活性，稳定性和抗肿瘤功效的最佳平衡。确认其低脑部穿透力后，我们进行了全面的临床前研究，包括多物种药代动力学概况，广泛的细胞机制研究，hERG分析和体内抗肿瘤生长作用测试，我们发现化合物19是潜在的BET蛋白药物候选者用于治疗癌症。
• [EN] HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] MODULATEURS HTT POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
  申请人：CHDI FOUNDATION INC

  公开号：WO2021231571A1

  公开（公告）日：2021-11-18

  Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

  以下提供了一些作为HTT调节剂有用的化合物。这些化合物在亨廷顿病的治疗中很有用。